• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对患有肺部基础疾病和免疫检查点抑制剂毒性患者的多学科处理方法。

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.

机构信息

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA.

出版信息

Oncologist. 2020 Nov;25(11):e1589-e1592. doi: 10.1634/theoncologist.2020-0266. Epub 2020 Sep 14.

DOI:10.1634/theoncologist.2020-0266
PMID:32701167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7648326/
Abstract

This commentary outlines the strategy employed by a multidisciplinary immune‐related toxicity team to evaluate patients who may be at high risk for the development of immune‐related toxicity, in particular, those with preexisting lung conditions and subsequent immune‐related pneumonitis.

摘要

本述评概述了一个多学科免疫相关毒性团队所采用的策略，用于评估可能存在发生免疫相关毒性高风险的患者，特别是那些有既往肺部疾病和随后发生免疫相关肺炎的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a02/7648326/ae15db711713/ONCO-25-e1589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a02/7648326/ae15db711713/ONCO-25-e1589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a02/7648326/ae15db711713/ONCO-25-e1589-g001.jpg

相似文献

1
A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.针对患有肺部基础疾病和免疫检查点抑制剂毒性患者的多学科处理方法。
Oncologist. 2020 Nov;25(11):e1589-e1592. doi: 10.1634/theoncologist.2020-0266. Epub 2020 Sep 14.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.
4
Immune-Checkpoint Blockade Therapy in Lymphoma.淋巴瘤的免疫检查点阻断治疗。
Int J Mol Sci. 2020 Jul 30;21(15):5456. doi: 10.3390/ijms21155456.
5
[Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].[免疫治疗机制进展及PD-1/PD-L1检查点抑制剂用于非小细胞肺癌脑转移的当前证据]
Zhongguo Fei Ai Za Zhi. 2020 Nov 20;23(11):976-982. doi: 10.3779/j.issn.1009-3419.2020.102.31. Epub 2020 Aug 10.
6
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.免疫检查点分子 B7-H1 在胰腺癌中的关键抗肿瘤作用。
Oncoimmunology. 2022 Mar 1;11(1):2043037. doi: 10.1080/2162402X.2022.2043037. eCollection 2022.
7
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.系统常规肌酸磷酸激酶检测在接受抗程序性死亡蛋白（配体）1 免疫检查点抑制剂治疗的无症状患者中对筛查心脏或神经肌肉免疫相关毒性无显著临床获益。
Eur J Cancer. 2021 Nov;157:383-390. doi: 10.1016/j.ejca.2021.08.045. Epub 2021 Sep 24.
8
Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.病例报告：在免疫检查点抑制剂联合放疗治疗肺鳞癌中，肺炎的临床症状先于影像学证据出现。
Front Immunol. 2022 Sep 15;13:998516. doi: 10.3389/fimmu.2022.998516. eCollection 2022.
9
There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.对另一种程序性细胞死亡蛋白1/程序性死亡配体1抑制剂存在未满足的需求。
J Thorac Oncol. 2022 Oct;17(10):1175-1177. doi: 10.1016/j.jtho.2022.07.1150.
10
[Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer].免疫检查点抑制剂在非小细胞肺癌临床诊疗中的研究进展
Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):713-717. doi: 10.3760/cma.j.cn112152-20200330-00276.

引用本文的文献

1
Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging.联合使用放射和免疫检查点抑制剂引起的肺炎 - 从不断发展的实验室生物标志物和临床影像学中预测和检测重叠的免疫相关不良反应的挑战。
Neoplasia. 2023 May;39:100892. doi: 10.1016/j.neo.2023.100892. Epub 2023 Apr 1.
2
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis.肿瘤急症护理诊所用于管理免疫相关不良事件：描述性分析。
Curr Oncol. 2022 Jun 17;29(6):4342-4353. doi: 10.3390/curroncol29060347.

本文引用的文献

1
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.癌症免疫治疗相关不良反应的多学科毒性小组。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.
2
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
3
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
序贯 PD-(L)1 阻断和奥希替尼治疗常出现严重免疫相关不良反应。
Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.
4
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.免疫检查点抑制剂治疗非小细胞肺癌患者的肺炎：发生率和危险因素。
J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.
5
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.纳武利尤单抗治疗伴预先存在的间质性肺病的非小细胞肺癌的疗效和安全性。
Thorac Cancer. 2018 Jul;9(7):847-855. doi: 10.1111/1759-7714.12759. Epub 2018 May 21.
6
The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.磨玻璃影范围是与非小细胞肺癌患者化疗相关的间质性肺病恶化的危险因素。
Cancer Chemother Pharmacol. 2018 Jan;81(1):131-139. doi: 10.1007/s00280-017-3476-5. Epub 2017 Nov 15.
7
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.纳武单抗治疗轻度特发性间质性肺炎的晚期非小细胞肺癌患者的一项试点试验。
Lung Cancer. 2017 Sep;111:1-5. doi: 10.1016/j.lungcan.2017.06.008. Epub 2017 Jun 17.
8
Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors.三名非小细胞肺癌患者在使用纳武单抗后发生严重急性间质性肺病，其影像学表现为肺肿瘤邻近气道阻塞。
J Infect Chemother. 2017 Dec;23(12):826-829. doi: 10.1016/j.jiac.2017.07.006. Epub 2017 Aug 18.
9
Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.接受PD-1检查点抑制剂治疗的黑色素瘤患者中免疫疗法诱导的结节病：病例系列及免疫表型分析
Int J Rheum Dis. 2017 Sep;20(9):1277-1285. doi: 10.1111/1756-185X.13076. Epub 2017 May 8.
10
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.PD-1 抑制剂以剂量非依赖性方式增加癌症患者肺炎的发生率和风险：一项荟萃分析。
Sci Rep. 2017 Mar 8;7:44173. doi: 10.1038/srep44173.